A Cochrane review included 70 studies with a total of 11 487 women. Vaginal PGE2 compared with placebo or no treatment non-significantly reduced the rate of unsuccessful vaginal delivery within 24 hours (RR 0.32, 95% CI 0.02 to 4.83; 2 trials, n=384). The risk of the cervix remaining unfavourable or unchanged was reduced (RR 0.41, 95% CI 0.27 to 0.65; 6 trials, n=567).There was a trend for lower caesarean section rates (RR 0.91, 95% CI 0.81 to 1.02; 36 trials, n=6599) although the risk of uterine hyperstimulation with fetal heart rate changes was increased (RR 3.16, 95% CI 1.67 to 5.98; 15 trials, n=1359).
PGE2 tablet, gel and pessary appear to be equally effective.